<DOC>
	<DOCNO>NCT00987389</DOCNO>
	<brief_summary>The purpose study determine whether plasma exchange well immunosuppressive therapy effective reduce death end-stage renal disease ( ESRD ) . The trial also study whether reduce cumulative dose regimen glucocorticoid effective standard disease regimen . The FDA-OOPD one funding source study .</brief_summary>
	<brief_title>Plasma Exchange Glucocorticoids Treatment Anti-Neutrophil Cytoplasm Antibody ( ANCA ) - Associated Vasculitis</brief_title>
	<detailed_description>Granulomatosis polyangiitis ( Wegener 's ) ( WG ) microscopic polyangiitis ( MPA ) syndromes primary systemic vasculitis associate anti-neutrophil cytoplasm antibody ( ANCA ) . Together , syndrome group ANCA-associated systemic vasculitis ( AAV ) . Plasma exchange , method rapidly remove potentially pathogenic ANCA mediator inflammation coagulation , show promise adjunctive therapy AAV improve early disease control improve rate renal recovery severe disease . Glucocorticoids ( steroid ) standard care treatment AAV . High dose glucocorticoid early disease , although reduce disease activity due anti-inflammatory immunosuppressive property , also increase risk infection , particularly elderly presence uremia . There randomized trial data guide glucocorticoid dose . Patients severe new relapse AAV pulmonary hemorrhage and/or renal disease eligible trial . Subjects participate study randomize receive one follow group ; 1 . Plasma exchange - 7 exchange , either standard low-dose glucocorticoid 2 . No plasma exchange , either standard low-dose glucocorticoid All study receive standard remission-induction therapy either cyclophosphamide rituximab .</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Microscopic Polyangiitis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>• New previous clinical diagnosis granulomatosis polyangiitis microscopic polyangiitis consistent ChapelHill consensus definition AND • Positive test proteinase 3ANCA myeloperoxidaseANCA AND Severe vasculitis define least one following : 1 . Renal involvement : Renal biopsy demonstrate focal necrotizing glomerulonephritis active urine sediment characterize glomerular haematuria red cell cast proteinuria AND eGFR &lt; 50 ml/min/1.73 m2 2 . Pulmonary hemorrhage due active vasculitis define : A compatible chest xray CT scan ( diffuse pulmonary infiltrates ) AND The absence alternative explanation pulmonary infiltrates ( e.g . volume overload pulmonary infection ) AND 3 . At least one following : Evidence alveolar hemorrhage bronchoscopic examination increasingly bloody return bronchoalveolar lavage Observed hemoptysis Unexplained anemia ( &lt; 10 g/dL ) document drop hemoglobin &gt; 1 g/dL ) Increased diffuse capacity carbon dioxide Provision inform consent patient surrogate decision maker A diagnosis vasculitis granulomatosis polyangiitis microscopic polyangiitis Positive antiglomerular basement membrane antibody test renal biopsy demonstrate linear glomerular immunoglobulin deposition Receipt dialysis &gt; 21 day immediately prior randomization prior renal transplant Age &lt; 15 year Pregnancy Inability unwillingness comply birth control/abstinence Treatment &gt; 1 IV dose cyclophosphamide and/or &gt; 14 day oral cyclophosphamide and/or &gt; 14 day prednisone/prednisolone ( &gt; 30 mg/day ) and/or &gt; 1 dose rituximab within 28 day immediately prior randomization A comorbidity , opinion investigator , precludes use cyclophosphamide , glucocorticoid , plasma exchange absolutely mandate use plasma exchange</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Vasculitis</keyword>
	<keyword>Granulomatosis Polyangiitis</keyword>
	<keyword>Microscopic Polyangiitis</keyword>
	<keyword>Wegener 's</keyword>
	<keyword>ANCA-Associated Vasculitis</keyword>
	<keyword>GPA</keyword>
	<keyword>MPA</keyword>
	<keyword>Treatment</keyword>
	<keyword>Plasma exchange</keyword>
	<keyword>Glucocorticoids</keyword>
	<keyword>ANCA-Positive</keyword>
</DOC>